Use of a KIT-specific monoclonal antibody to bypass imatinib resistance ingastrointestinal stromal tumors.

摘要

Acquired resistance to imatinib is a significant problem for the clinicalmanagement of gastrointestinal stromal tumor (GIST) patients, and second-linesmall molecules have shown limited efficacy in this setting. We have recentlydemonstrated that a monoclonal antibody targeting KIT could potentially bypassimatinib resistance in preclinical models of GIST.